MetabolomicsWorkbenchapplication/xmlhttp://www.metabolomicsworkbench.org/rest/study/study_id/ST000423/mwtabprimaryOK200MetabolomicsMass SpectrometryESIMus Musculushttp://www.metabolomicsworkbench.org/data/DRCCMetadata.php?Mode=Study&StudyID=ST000423Treatment:Resident macrophageTreatment:Bone marrow macrophageUniversity of California, DavisCellsUPLC POSITIVE ION MODE. UPLC NEGATIVE ION MODE.MetabolomicsWorkbenchPE (p-36:4) or PE (o-36:5)PE (38:4)TG (54:1)PC (38:4)SM (d42:1)PC (36:2)PE (36:2)PC (34:0)PC (p-34:0) or PC (o-34:1)PC (40:8)TG (48:1)TG (60:2)SM (d36:1)PE (p-38:4) or PE (o-38:5)TG (56:2)PC (p-38:3) or PC (o-38:4)PE (p-40:5) or PE (o-40:6)PC (p-40:4) or PC (o-40:5)TG (58:4)TG (51:1)PC (38:5)SM (d42:2)PC (36:3)PE (34:1)Ceramide (d34:1)PC (p-38:5) or PC (o-38:6)Ceramide (d40:1)PE (p-40:7) or PE (o-40:8)PC (34:1)PC (p-40:6) or PC (o-40:7)SM (d39:1)PC (p-42:4) or PC (o-42:5)TG (48:0)SM (d34:1)TG (56:1)SM (d40:1)GlcCer (d41:1)PE (36:4)SM (d42:3)PE (38:6)Gal-Gal-Cer(d18:1/16:0) or Lactosylceramide(d18:1/16:0)PC (38:2)Ceramide (d34:0)PC (33:1)PC (40:6)Ceramide (d42:2)TG (14:0/14:0/14:0)FA (20:1) (eicosenoic acid)SM (d34:2)TG (52:4)TG (58:2)PC (28:0)TG (54:6)PE (p-38:5) or PE (o-38:6)TG (50:2)Ceramide (d18:1/23:0)PC (p-38:4) or PC (o-38:5)PE (p-40:6) or PE (o-40:7)CholesterolGlcCer(d14:1(4E)/20:0(2OH))PC (p-42:3) or PC (o-42:4)Ceramide (d36:1)PC (38:3)PC (36:1)PE (p-36:2) or PE (o-36:3)PC (p-36:1) or PC (o-36:2)Ceramide (d42:1)PC (31:0)PC (40:7)TG (58:1)PC (p-42:5) or PC (o-42:6)FA (22:6) (docosahexaenoic acid)PC (o-32:0)TG (52:3)SM (d43:2)TG (50:1)PC (34:4)PE (p-36:5) or PE (o-36:6)Ceramide (d33:1)PC (40:4)PC (35:1)PE (p-40:4) or PE (o-40:5)PC (30:0)PC (42:6)SM (d32:1)TG (54:4)TG (56:6)GlcCer (d42:1)TG (52:2)PE (p-36:1) or PE (o-36:2)TG (50:0)SM (d41:1)LPC (16:0)PC (33:0)PC (40:5)PC (30:1)TG (58:8)PC (42:7)TG (54:3)FA (20:4) (arachidonic acid)TG (56:5)TG (52:1)FA (24:0) (lignoceric acid)Ceramide (d38:1)GlcCer (d42:2)PC (o-34:0)PC (p-36:3) or PC (o-36:4)PC (38:6)SM (d41:2)LPC (18:1)CE (18:1)PC (36:4)PC (34:2)PC (p-36:4) or PC (o-36:5)PE (p-34:1) or PE (o-34:2)Ceramide (d41:1)PC (32:0)PC (p-40:3) or PC (o-40:4)SM (d38:1)TG (49:0)PE (p-34:2) or PE (o-34:3)PC (p-34:1) or PC (o-34:2)TG (54:2)TG (56:4)TG (52:0)GlcCer (d40:1)FA (24:1) (nervonic acid)LPC (18:0)TG (46:0)PC (36:5)PC (34:3)FA (22:0) (behenic acid)CE (22:6)PC (32:1)TG (58:6)PC (42:5)TG (48:2)CE (20:4)SM (d33:1)development, Haemobartonella, PPLO, postnatal development., Asterococcus <mycoplasmas>, growth pattern, Pleuropneumonia-Like Organisms, non-developmental growth, Bovimyces, postnatal growth, Mycoplasma putrefaciens, Borrelomyces, growth and development, Eperythrozoon, growth, Pleuropneumonia Like Organisms, Pleuropneumonia, Asteromyces <mycoplasmas>iones., Ionen, ion, Ion, ions, ionesfalseDifferences in mycoplasma growth due to different mediumsST00042310090